Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

ABSTRACT:

Background

National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31 suggested the efficacy of adjuvant trastuzumab, even in HER2-negative breast cancer. This finding prompted us to develop a predictive model for degree of benefit from trastuzumab using archived tumor blocks from B-31.

Methods

Case subjects with tumor blocks were randomly divided into discovery (n = 588) and confirmation cohorts (n = 991). A predictive model was built from the discovery cohort through gene expression profiling of 462 genes with nCounter assay. A predefined cut point for the predictive model was tested in the confirmation cohort. Gene-by-treatment interaction was tested with Cox models, and correlations between variables were assessed with Spearman correlation. Principal componen

SUBMITTER: Pogue-Geile KL 

PROVIDER: S-EPMC3848987 | biostudies-literature | 2013 Dec

REPOSITORIES: biostudies-literature